C0002871||Anemia
C0011860||type 2 diabetes
C0035648||risk factors
C0033325||prognosis
C0035648||risk factors
C0033325||prognosis
C0002871||anemia
C0030701||representative
C0011860||type 2 diabetes
C2603343||Fremantle Diabetes Study Phase II
C2603343||FDS2
C2603343||Busselton Diabetes Study
C2603343||Busselton Diabetes Study
C0599755||cohorts
C2603343||Busselton Diabetes Study
C0679646||participants
C0011847||diabetes
C0936012||analyzed
C0002871||anemia
C0019046||hemoglobin
C0178913||sample
C2603343||FDS2
C0002871||anemia
C0206031||logistic regression
C0010235||Cox proportional hazards modeling
C0035648||predictors
C0011065||death
C0002871||anemia
C2603343||FDS2
C0679646||participants
C2603343||Busselton Diabetes Study
C2603343||Busselton Diabetes Study
C0679646||participants
C0011847||diabetes
C2603343||FDS2
C0002871||anemia
C0035648||risk factor
C0427408||serum vitamin B12
C0241012||serum ferritin
C1277709||transferrin saturation
C0428413||serum testosterone
C1257987||glitazone
C0087111||therapy
C3811844||estimated glomerular filtration rate
C3811844||estimated glomerular filtration rate
C4282132||malignancy
C0019045||hemoglobinopathy
C0857322||anemic
C0857322||non-anemic
C2603343||FDS2
C0035648||predictors
C1704258||Aboriginality
C3811844||estimated glomerular filtration rate
C0002871||anemia
C0011860||Type 2 diabetes
C0002871||anemia
C0035648||risk factors
C0150312||present
C0002871||Anemia
C2749787||increased risk of death
C0035648||predictors